Capricor Therapeutics CAPR Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's business segments — net income loss?
- Capricor Therapeutics (CAPR) reported business segments — net income loss of -$33.94M in Q1 2026.
- How has Capricor Therapeutics's business segments — net income loss changed year-over-year?
- Capricor Therapeutics's business segments — net income loss decreased by 39.2% year-over-year, from -$24.39M to -$33.94M.
- What does business segments — net income loss mean?
- This represents the final bottom-line profit or loss for the business segment after all expenses, taxes, and non-operating items have been deducted. It is the definitive measure of the company's financial performance for the period. For development-stage biotech companies, this typically reflects the net cash burn required to sustain operations.